SEC Form SC 13G/A filed by Core Laboratories N.V. (Amendment)

2/14/23 8:32:09 AM ET

Oilfield Services/Equipment

Energy

Get the next $CLB alert in real time by email

SC 13G/A 1 clb13g10th1222.txt CORE LABORATORIES N.V. - 12/31/2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No._10_) CORE LABORATORIES N.V. ------------------------------------------------------------------------------- (Name of Issuer) Common Shares ------------------------------------------------------------------------------- (Title of Class of Securities) N22717107 ------------------------------ (CUSIP Number) 12/31/2022 ------------------------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) CUSIP NO. N22717107 --------- ------------------------------------------------------------------------------- 1 NAMES OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY). EARNEST Partners, LLC ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [ ] (b) [ ] ------------------------------------------------------------------------------- 3 SEC USE ONLY ------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware ------------------------------------------------------------------------------- 5 SOLE VOTING POWER 2,639,073 NUMBER OF ----------------------------------------------------------------- SHARES BENEFICIALLY 6 SHARED VOTING POWER 0 OWNED BY ----------------------------------------------------------------- EACH REPORTING 7 SOLE DISPOSITIVE POWER 3,573,101 PERSON WITH ----------------------------------------------------------------- 8 SHARED DISPOSITIVE POWER 0 ------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,573,101 ------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)[ ] ------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.7% ------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) ------------------------------------------------------------------------------- IA ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- Item 1 (a) Name of Issuer CORE LABORATORIES N.V. (b) Address of Issuer's Principal Executive Offices Van Heuven Goedhartlaan 7 B 1181 LE Amstelveen, The Netherlands Item 2 (a) Name of Person Filing EARNEST Partners, LLC (b) Address of Principal Business Office or, if none, Residence 1180 Peachtree Street NE, Suite 2300, Atlanta, Georgia 30309 (c) Citizenship Delaware (d) Title of Class of Securities Common Shares (e) CUSIP Number N22717107 Item 3. If this statement is filed pursuant to 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under section 15 of the Act (b) [ ] Bank as defined in section 3(a)(6) of the Act (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (e) [X] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (j) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J). Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 3,573,101 (b) Percent of class: 7.7% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote 2,639,073 (ii) Shared power to vote or to direct the vote 0 (iii) Sole power to dispose or to direct the disposition of 3,573,101 (iv) Shared power to dispose or to direct the disposition of 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ] Item 6. Ownership of More than Five Percent on Behalf of Another Person. EARNEST Partners, LLC is filing as an investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). No client interest relates to more than five percent of the class. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. Not Applicable Item 8. Identification and Classification of Members of the Group. Not Applicable Item 9. Notice of Dissolution of a Group Not Applicable Item 10. Certification (a) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(b): By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. (b) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(c): By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 13, 2023 ---------------------------------- Date /s/ James M. Wilson ---------------------------------- Signature James M. Wilson Chief Compliance Officer ---------------------------------- Name/Title Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001) ACN/Form 13G (C) 2006: Advisor Consultant Network, Inc.

Get the next $CLB alert in real time by email

Date	Price Target	Rating	Analyst
3/12/2025	$15.00 → $16.00	Sell → Neutral	Citigroup
6/30/2023	$22.00 → $21.00	Neutral → Sell	Citigroup
4/18/2023	$21.50	Neutral → Underperform	BofA Securities
1/9/2023		Underperform → Neutral	BofA Securities
10/7/2022	$24.00 → $17.00	Sell → Neutral	Citigroup
9/26/2022	$20.00	Equal-Weight → Underweight	Morgan Stanley
4/18/2022	$19.50 → $21.30	Neutral → Underweight	Piper Sandler
1/18/2022	$32.00 → $30.00	Equal-Weight	Morgan Stanley

SEC Form SC 13G/A filed by Core Laboratories N.V. (Amendment)

Chat with this insight

Recent Analyst Ratings for
$CLB

$CLB
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Core Labs upgraded by Citigroup with a new price target

Core Labs downgraded by Citigroup with a new price target

Core Labs downgraded by BofA Securities with a new price target

$CLB
Financials

Live finance-specific insights

$CLB
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CORE LAB REPORTS FIRST QUARTER 2025 RESULTS

CORE LABORATORIES ANNOUNCES TIMING OF FIRST QUARTER 2025 EARNINGS RELEASE AND CONFERENCE CALL

CORE LAB REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS

Director Temeng Kwaku converted options into 9,317 shares, increasing direct ownership by 57% to 25,528 units (SEC Form 4)

Director Murray Katherine converted options into 9,317 shares, increasing direct ownership by 78% to 21,221 units (SEC Form 4)

Director Klingensmith Harvey Robert converted options into 9,317 shares, increasing direct ownership by 29% to 41,962 units (SEC Form 4)

$CLB
SEC Filings

Core Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form DEFA14A filed by Core Laboratories Inc.

SEC Form DEF 14A filed by Core Laboratories Inc.

$CLB
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Core Laboratories Inc. (Amendment)